Nov 5, 2025 06:02PM Dianthus Therapeutics (DNTH) Misses Q3 EPS by 97c

Oct 29, 2025 03:31PM Dianthus presents new data on claseprubart for myasthenia gravis

Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'

Oct 16, 2025 12:24PM Dianthus Therapeutics (DNTH) PT Raised to $60 at Oppenheimer

Oct 16, 2025 09:57AM TD Cowen on Dianthus (DNTH): 'the favorable economics of the deal will not impact prior guidance of cash runway into 2028'

Oct 16, 2025 09:56AM Guggenheim on Dianthus (DNTH) and Leads BioLabs Deal: 'We view this as a well-structured deal'

Oct 14, 2025 06:07AM Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy

Sep 16, 2025 04:22PM Clear Street Starts Dianthus Therapeutics (DNTH) at Buy, PT $100

Sep 10, 2025 10:51AM Dianthus Therapeutics (DNTH) PT Raised to $66 at Jefferies, 'We believe DNTH is undervalued'

Sep 9, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Sep 9, 2025 05:04AM Dianthus Therapeutics (DNTH) PT Raised to $63 at Raymond James

Sep 8, 2025 12:19PM Dianthus Therapeutics (DNTH) PT Raised to $100 at Guggenheim

Sep 5, 2025 02:34PM Guggenheim on Dianthus Therapeutics (DNTH): 'remains one of our Top Picks'

Aug 22, 2025 07:15AM Cantor Fitzgerald Reiterates Overweight Rating on Dianthus Therapeutics (DNTH)

Aug 14, 2025 06:09AM Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Jul 28, 2025 06:11AM Dianthus Therapeutics (DNTH) PT Raised to $92 at Guggenheim

Jul 14, 2025 06:49AM Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Jul 2, 2025 06:02AM William Blair Starts Dianthus Therapeutics (DNTH) at Outperform

Jun 17, 2025 07:08AM Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

May 22, 2025 04:10PM Dianthus Therapeutics (DNTH) Appoints Simon Read, Ph.D., to Board of Directors

May 13, 2025 06:57AM Dianthus Therapeutics (DNTH) Misses Q1 EPS by 82c

May 5, 2025 07:02AM Dianthus Therapeutics (DNTH) Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

Mar 12, 2025 07:39AM Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Mar 12, 2025 06:33AM Dianthus Therapeutics (DNTH) Misses Q4 EPS by 81c

Mar 5, 2025 07:02AM Dianthus Therapeutics (DNTH) Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango to Board

Dec 20, 2024 05:31AM TD Cowen Starts Dianthus Therapeutics (DNTH) at Buy

Nov 11, 2024 07:51AM Dianthus Therapeutics (DNTH) PT Raised to $52 at Oppenheimer

Nov 8, 2024 06:24AM Dianthus Therapeutics (DNTH) Misses Q3 EPS by 74c

Oct 7, 2024 06:54AM Baird Reiterates Outperform Rating on Dianthus Therapeutics (DNTH)

Oct 4, 2024 10:10AM Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Oct 1, 2024 04:38PM Dianthus Therapeutics (DNTH) Files $500M Mixed Shelf

Oct 1, 2024 04:34PM Dianthus Therapeutics (DNTH) Files for 23.66M Share Offering by Selling Stockholders

Sep 26, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

Aug 9, 2024 06:38AM Dianthus Therapeutics (DNTH) Misses Q2 EPS by 51c

Jul 26, 2024 04:58AM Baird Starts Dianthus Therapeutics (DNTH) at Outperform

Jun 12, 2024 07:00AM Dianthus Therapeutics (DNTH) Granted FDA Clearance to Initiate Phase 2 Trial of DNTH103